Cyclosporine A and tacrolimus inhibit bladder cancer growth through down-regulation of NFATc1

Oncotarget

Volumn 6, Issue 3, 2015, Pages 1582-1593

  Kawahara, Takashi ^a,b   Kashiwagi, Eiji ^a   Ide, Hiroki ^a   Li, Yi ^b   Zheng, Yichun ^a,b   Miyamoto, Yurina ^b   Netto, George J ^a   Ishiguro, Hitoshi ^a,b   Miyamoto, Hiroshi ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Bladder cancer; Cyclosporine; NFAT; Tacrolimus; Tumor progression

Indexed keywords

CYCLOOXYGENASE 2; CYCLOSPORIN A; GELATINASE A; GELATINASE B; MYC PROTEIN; SMALL INTERFERING RNA; TACROLIMUS; TRANSCRIPTION FACTOR NFAT; TRANSCRIPTION FACTOR NFATC1; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CYCLOSPORIN; NFATC1 PROTEIN, HUMAN;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BLADDER CANCER; BLADDER CANCER CELL LINE; CANCER INHIBITION; CELL INVASION; CELL MIGRATION; CELL NUCLEUS; CELL VIABILITY; CELLULAR DISTRIBUTION; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOUSE; MUSCLE INVASIVE BLADDER CANCER; NONHUMAN; TISSUE MICROARRAY; TUMOR XENOGRAFT; ANIMAL; DRUG EFFECTS; DRUG SCREENING; GENETICS; METABOLISM; NONOBESE DIABETIC MOUSE; PATHOLOGY; SCID MOUSE; TUMOR CELL LINE; URINARY BLADDER NEOPLASMS;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CYCLOSPORINE; DOWN-REGULATION; HUMANS; MALE; MICE; MICE, INBRED NOD; MICE, SCID; NFATC TRANSCRIPTION FACTORS; TACROLIMUS; URINARY BLADDER NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84922750454     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2750     Document Type: Article

References (36)

1. Shaw JP, Utz PJ, Durand DB, Toole JJ, Emmel EA, Crabtree GR. Identification of a putative regulator of early T cell activation genes. Science. 1988; 241:202-205.
2. Macian F. NFAT proteins: key regulators of T-cell development and function. Nat Rev Immunol. 2005; 5:472-484.
3. Hogan PG, Chen L, Nardone J, Rao A. Transcriptional regulation by calcium, calcineurin, and NFAT. Genes Dev. 2003; 17:2205-2232.
4. Flanagan WM, Corthésy B, Bram RJ, Crabtree GR. Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A. Nature. 1991; 352:803-807.
5. 2+/calcineurin signaling pathway. EMBO J. 2006; 25:3714-3724.
6. Chen Z-L, Zhao S-H, Wang Z, Qiu B, Li B-Z, Zhou F, Tan X-G, He J. Expression and unique functions of four nuclear factor of activated T cells isoforms in non-small cell lung cancer. Chin J Cancer. 2011; 30:62-68.
7. Wang S, Kang X, Cao S, Cheng H, Wang D, Geng J. Calcineurin/NFATc1 pathway contributes to cell proliferation in hepatocellular carcinoma. Dig Dis Sci. 2012; 57:3184-3188.
8. Flockhart RJ, Armstrong JL, Reynolds NJ, Lovat PE. NFAT signalling is a novel target of oncogenic BRAF in metastatic melanoma. Br J Cancer. 2009; 101:1448-1455.
9. Seifert A, Rau S, Küllertz G, Fischer B, Santos AN. TCDD induces cell migration via NFATc1/ATX-signaling in MCF-7 cells. Toxicol Lett. 2009; 184:26-32.
10. Robbs BK, Cruz AL, Werneck MB, Mognol GP, Viola JP. Dual roles for NFAT transcription factor genes as oncogenes and tumor suppressors. Mol Cell Biol. 2008; 28:7168-7181.
11. Kulkarni RM, Greenberg JM, Akeson AL. NFATc1 regulates lymphatic endothelial development. Mech Dev. 2009; 126:350-365.
12. Fougère M, Gaudineau B, Barbier J, Guaddachi F, Feugeas JP, Auboeuf D, Jauliac S. NFAT3 transcription factor inhibits breast cancer cell motility by targeting the Lipocalin 2 gene. Oncogene. 2010; 29:2292-2301.
13. 2+ entry and proliferation of prostate cancer epithelial cells. Cancer Res. 2006; 66:2038-2047.
14. 2+/NFAT-dependent pathways. Oncogene. 2007; 26:7380-7385.
15. Sales KJ, Maldonado-Pérez D, Grant V, Catalano RD, Wilson MR, Brown P, Williams AR, Anderson RA, Thompson EA, Jabbour HN. Prostaglandin F2α-F-prostanoid receptor regulates CXCL8 expression in endometrial adenocarcinoma cells via the calcium-calcineurin-NFAT pathway. Biochim Biophys Acta. 2009; 1793:1917-1928.
16. Köenig A, Linhart T, Schlengemann K, Reutlinger K, Wegele J, Adler G, Singh G, Hofmann L, Kunsch S, Büch T, Schäfer E, Gress TM, Fernandez-Zapico ME, et al. NFAT-induced histone acetylation relay switch promotes c-Myc-dependent growth in pancreatic cancer cells. Gastroenterology. 2010; 138:1189-1199.e2.
17. Yiu GK, Kaunisto A, Chin YR, Toker A. NFAT promotes carcinoma invasive migration through glypican-6. Biochem J. 2011; 440:157-166.
18. Tauro S, MacCallum S, Groves MJ, Rojnuckarin P, Assanasen T, Feldman AL, Robson A, Marschalkó M, Kini H, Alzolibani AA, Al Robaee A, Al Shobaili HA, Alfawzan S, et al. Immunohistochemical localization of cellular NFATc1 does not predict clinical responses to ciclosporin in subcutaneous panniculitis-like T-cell non-Hodgkin lymphoma. Br J Dermatol. 2010; 162:887-889.
19. Kawahara T, Kashiwagi E, Li Y, Zheng Y, Miyamoto Y, Netto GJ, Ishiguro H, Miyamoto H. Cyclosporine A and tacrolimus inhibit urothelial tumorigenesis. Mol Carcinogen. 2014; In press.
20. Miyamoto H, Miller JS, Fajardo DA, Lee TK, Netto GJ, Epstein JI. Non-invasive papillary urothelial neoplasms: The 2004 WHO/ISUP classification system. Pathol Int. 2010; 60:1-8.
21. Frauman DA, Klee CB, Bierer BE, Burakoff SJ. Calcineurin phosphatase activity in T lymphocytes is inhibited by FK 506 and cyclosporine A. Proc Natl Acad Sci USA. 1992; 89:3686-3690.
22. Werneck MB, Hottz E, Bozza PT, Viola JPB. Cyclosporin A inhibits colon cancer cell growth independently of the calcineurin pathway. Cell Cycle. 2012; 11:3997-4008.
23. Böttiger Y, Brattström C, Tydén G, Säwe J, Groth CG. Tacrolimus whole blood concentrations correlate closely to side-effects in renal transplant recipients. Br J Clin Pharmacol. 1999; 48:445-448.
24. Kung L, Halloran PF. Immunophilins may limit calcineurin inhibition by cyclosporine and tacrolimus at high drug concentrations. Transplantation. 2000; 70:327-335.
25. Periyasamy S, Warrier M, Tillekeratne MP, Shou W, Sanchez ER. The immunophilin ligands cyclosporin A and FK506 suppress prostate cancer cell growth by androgen receptor-dependent and-independent mechanisms. Endocrinology. 2007; 148:4716-4726.
26. Miyamoto H, Yang Z, Chen Y-T, Ishiguro H, Uemura H, Kubota Y, Nagashima Y, Chang Y-J, Hu Y-C, Tsai M-Y, Yeh S, Messing EM, Chang C. Promotion of bladder cancer development and progression by androgen receptor signals. J Natl Cancer Inst. 2007; 99:558-568.
27. Li Y, Izumi K, Miyamoto H. The role of the androgen receptor in the development and progression of bladder cancer. Jpn J Clin Oncol. 2012; 42:569-577.
28. Li Y, Zheng Y, Izumi K, Ishiguro H, Ye B, Li F, Miyamoto H. Androgen activates β-catenin signaling in bladder cancer cells. Endocr Relat Cancer. 2013; 20:293-304.
29. Aramburu J, Yaffe MB, López-Rodríguez C, Cantley LC, Hogan PG, Rao A. Affinity-driven peptide selection of an NFAT inhibitor more selective than cyclosporin A. Science. 1999; 284:2129-2133.
30. Noguchi H, Matsushita M, Okitsu T, Moriwaki A, Tomizawa K, Kang S, Li ST, Kobayashi N, Matsumoto S, Tanaka K, Tanaka N, Matsui H. A new cell-permeable peptide allows successful allogeneic islet transplantation in mice. Nat Med. 2004; 10:305-309.
31. Karanam BV, Miller RR, Colletti A, Montgomery T, Carey KD, Hawkins T, Tang YS, Lavin M, Stearns RA, Chiu SHL, Vincent SH. Disposition of L-732,531, a potent immunosuppressant, in rats and baboons. Drug Metab Dispos. 1998; 26:949-957.
32. Abel MD, Aspeslet LJ, Freitag DG, Naicker S, Trepanier DJ, Kneteman NM, Foster RT, Yatscoff RW. ISATX247: a novel calcineurin inhibitor. J Heart Lung Transplant. 2001; 20:161.
33. Roehrl MH, Kang S, Aramburu J, Wagner G, Rao A, Hogan PG. Selective inhibition of calcineurin-NFAT signaling by blocking protein-protein interaction with small organic molecules. Proc Natl Acad Sci USA. 2004; 101:7554-7559.
34. Zheng Y, Izumi K, Li Y, Ishiguro H, Miyamoto H. Contrary regulation of bladder cancer cell proliferation and invasion by dexamethasone-mediated glucocorticoid receptor signals. Mol Cancer Ther. 2012; 11:2621-2632.
35. Izumi K, Zheng Y, Hsu J-W, Chang C, Miyamoto H. Androgen receptor signals regulate UDP-glucuronosyltransferases in the urinary bladder: A potential mechanism of androgen-induced bladder carcinogenesis. Mol Carcinogen. 2013; 52:94-102.
36. Miyamoto H, Izumi K, Yao JL, Li Y, Yang Q, McMahon LA, Gonzalez-Roibon N, Hicks DG, Tacha D, Netto GJ. GATA binding protein 3 is down-regulated in bladder cancer yet strong expression is an independent predictor of poor prognosis in invasive tumor. Hum Pathol. 2012; 43:2033-2040.